Bazedoxifene does not share estrogens effects on IgG sialylation.

Area of Science:

• Immunology
• Endocrinology
• Glycobiology

Background:

• Rheumatoid arthritis (RA) incidence rises with menopause, coinciding with decreased estrogen levels.
• Estrogen therapy can reduce IgG pathogenicity by increasing sialylation, thereby inhibiting Fc gamma receptor binding.
• Selective estrogen receptor modulators (SERMs) offer potential estrogenic benefits with fewer side effects.

Purpose of the Study:

• To investigate the impact of the SERM bazedoxifene on IgG and total serum protein sialylation.
• To evaluate the effects of estrogen and bazedoxifene in a mouse model of postmenopausal status and autoimmune predisposition.

Main Methods:

• Ovariectomy was performed on C57BL6 mice to mimic postmenopausal conditions.
• Mice were immunized with ovalbumin and subsequently treated with estradiol, bazedoxifene, or vehicle.
• Analysis included IgG levels, IgG sialylation, total serum protein sialylation, and mRNA expression of glycosyltransferases.

Main Results:

• Estrogen treatment increased IgG levels but had a limited effect on IgG sialylation.
• Bazedoxifene showed a trend towards increasing sialic acids in plasma cells, but without statistical significance.
• Neither estrogen nor bazedoxifene significantly altered overall serum protein sialylation.
• Both treatments had minor effects on glycosyltransferase mRNA expression in specific tissues.

Conclusions:

• Bazedoxifene did not significantly alter IgG sialylation in this mouse model.
• Further research is needed to determine the therapeutic potential of SERMs in autoimmune diseases like RA.
• Estrogen and bazedoxifene may influence glycosyltransferase expression, warranting further investigation.